Vaccines for Porcine Coronaviruses
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".
Deadline for manuscript submissions: 1 December 2025 | Viewed by 264
Special Issue Editor
Interests: coronavirus; virus-like particle vaccine; adjuvant; mucosal vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Porcine coronaviruses primarily infect pigs, causing various diseases that impact their respiratory or gastrointestinal systems. Common species include Porcine Epidemic Diarrhea Virus (PEDV), Transmissible Gastroenteritis Virus (TGEV), and Porcine Deltacoronavirus (PDCoV). These viruses can lead to significant economic losses in the swine industry due to their high morbidity and mortality rates, particularly in neonatal piglets. For example, a swine CoV infection in October 2010 killed more than 1 million piglets in China. In 2013, swine CoV outbreaks in the United States of America (USA), Canada, and Mexico killed more than 8 million piglets in the USA alone. Research and control measures, including biosecurity practices and vaccine development, are critical for managing the spread of these viruses in pig populations.
The development of vaccines for porcine coronaviruses focuses on creating effective immunization strategies to prevent the spread of these viruses among swine populations. This involves identifying suitable viral antigens, employing various vaccine platforms such as inactivated, live-attenuated, or recombinant vaccines, and ensuring their safety and efficacy through extensive trials. Advances in molecular biology and virology have also enabled the exploration of novel approaches, such as mRNA-based vaccines or vector-based delivery systems, to enhance immune responses and provide robust protection against porcine coronavirus infections.
This Special Issue addresses past and ongoing efforts to develop vaccines against porcine coronaviruses. It welcomes original research articles and reviews whose scope includes, but is not limited to, the following: the development of porcine coronavirus vaccines; the immunogenicity of porcine coronavirus vaccines; and challenges in the development of porcine coronavirus vaccines.
I look forward to receiving your contributions.
Dr. Jung-Eun Park
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- porcine coronavirus
- porcine epidemic diarrhea virus (PEDV)
- transmissible gastroenteritis virus (TGEV)
- porcine deltacoronavirus (PDCoV)
- swine acute diarrhea syndrome coronavirus (SADS-CoV)
- porcine respiratory coronavirus (PRCV)
- porcine hemagglutinating encephalomyelitis virus (PHEV)
- vaccine
- immune response
- protective efficacy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
